We serve 1-butyl-3-methylimidazolium perchlorate CAS:220956-35-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
English Name: 1-butyl-3-methylimidazolium perchlorate
Synonyms:1-butyl-3-methylimidazolium perchlorate
Molecular Formula: C8H15O4N2Cl
Molecular Weight: 238.67
CAS No.: 220956-35-4
Purity: 99%
Technical Information
| Appearance: | Purity: |
| NMR: Passed | null |
| Solubility: | Insolubility: |
|
Impurity content: (1) Methylimidazole content: < 1000 ppm; (2) Halogen content: < 1000 ppm; (3) Water content: < 1000 ppm |
|
Physics-Chemistry Properties
| Melting point: -78(Tg) | Decomposition temperature: |
| Conductivity: 1.8ms/cm | Electrochemical window: 3.6V |
| Viscosity: 47.5cp | Density: 1.26g/cm3 |
Our company has been engaged in the R&D, production of ionic liquids and related technologies for more than ten years. Since 2007, our company has supplied ionic liquid reagents to customers, and can provide customers with ionic liquid products from grams to hundreds of tons. The main product series are: Imidazolium ionic liquids, single-substituted Im ionic liquids, Disubstituted Im ionic liquids, Tri-Substituted Im ionic liquids, Pyrilidinium ionic liquids, Ammonium ionic liquids, Phosphonium ionic liquids, Pyrrolidinium ionic liquids, Piperidinium ionic liquids, Functionized ionic liquids, Vinyl-Based ionic liquids, Hydroxyl-Based ionic liquids, Ether-Based ionic liquids, Ester-Based ionic liquids, Carboxyl-Based ionic liquids, Nitrile-Based ionic liquids, Amido-Based ionic liquids, SulfoAcid-Based ionic liquids, Benzyl-Based ionic liquids, Guanidine-Based ionic liquids, Oxonium salts
Contact us for information like 1-butyl-3-methylimidazolium perchlorate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-butyl-3-methylimidazolium perchlorate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-butyl-3-methylimidazolium perchlorate Use and application,1-butyl-3-methylimidazolium perchlorate technical grade,usp/ep/jp grade.
Related News: This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?Methyl 2-methoxy-5-sulfamoylbenzoate manufacturer These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation? whose founders — in addition to Ed Damiano — include other parents of children with type 1 diabetes and people with type 1 diabetes. Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible.4-Boc-aminopiperidine supplier These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation? whose founders — in addition to Ed Damiano — include other parents of children with type 1 diabetes and people with type 1 diabetes. Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible.2,2'-dibromo-9,9'-spirobi[fluorene] vendor In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers.Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.
